NCT07470996 (T-START-NR) is a clinical trial of Allogenic stem cell transplant (ASCT) in Peripheral T Cell Lymphoma, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT07470996?

Interventions in NCT07470996: Allogenic stem cell transplant (ASCT), Salvage Therapy.

What condition does NCT07470996 study?

NCT07470996 studies Peripheral T Cell Lymphoma.

Is NCT07470996 still recruiting?

NCT07470996 is currently recruiting now. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT07470996: T-START-NR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Recruiting now Last updated 13 March 2026

What this trial tests

trial testing Allogenic stem cell transplant (ASCT) in Peripheral T Cell Lymphoma in 58 participants. Currently enrolling.

Timeline

1 October 2025

Primary endpoint
30 May 2029

30 September 2029

Quick facts

Lead sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	58
Start date	1 October 2025
Primary completion	30 May 2029
Estimated completion	30 September 2029
Sites	1 location across China

Drugs / interventions tested

Allogenic stem cell transplant (ASCT) — full drug profile →
Salvage Therapy — full drug profile →

Conditions studied

Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 70, any sex, with Peripheral T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens. It aims to evaluate the efficacy and safety of Allo-HSCT and alternative salvage regimens in the treatment of peripheral T-cell lymphoma that has achieved no response (NR) after first-line therapy. During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. Group assignment (Allo-HSCT vs. alternative salvage regimens) will be determined taking into account the availability of a matched donor and the patient's preference. The study plans to enroll 29 patients in each group. Data on demographics and medical history will be collected, and assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, and bone marrow pathology will be performed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Allogenic stem cell transplant (ASCT)

Trials testing the same drug.

NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting
NCT00520130 — Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System · Phase 1, PHASE2 · completed

Other recruiting trials for Peripheral T Cell Lymphoma

Currently open trials in the same condition.

NCT07414758 — Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy · Phase 3 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07389616 — A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell · Phase 2, PHASE3 · recruiting
NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT06667466 — New Laser and Suction Sheath for Kidney Stone Treatment · not yet recruiting
NCT07043374 — Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway · not yet recruiting
NCT07415226 — Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT07439120 — Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07470996 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07470996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing